With What they have in their pipe line for HEP C alone makes them worth 5 Billion..When the news comes out later this year on the on going trial will be the biggest catalyst for GILD to step up yo plate.6 weeks to 4 weeks duration and rib free..Best in Class.And You Cant Compete With That....
Buy out at 50 plus
i will just wait
Its a good time to continue to add to ache.The news on trials will be out later this year..If still best in class and reduced cure time to 4 weeks,it will be all over..40 plus...watching every day is painful,,but look at it as if it were on sale
ACHN had a best in class drug. You ant compete with that. At the end of the day. The people suffering from this disease would rather be cured in 4 to 6 weeks with 100% efficacy. Not 8 to 12 with 92%
They know they want to buy ACHN,so they send a lame press release tanking both stocks,knowing all the well that GILD will bounce because its a giant,and they put pressure on achn..at the end of the day
$40.00 is where this will get bought..
When buy out or partnering came up the shushed it,The results are amazing with one treatment,going forward this could be to als what GILD is to Hep c..Ive had 3 people that I know die of ALS its brutal and should be fast tracked..No where but up,forget they nay sayers
I would highlight that we observed not only a highly meaningful reduction in ALS progression on mean ALSFRS and FVC, but we saw subjects with prolonged stabilization and even improvements in function, and all this was achieved with just a single dose of NurOwn™. We are excited to proceed to a multi-dose study to see if these positive results can be amplified and extended by administering repeated doses."
It would be taking a step backward with extra risk...
Deutche bank price target $125.00.....A few more up grades forth coming
Its an over reaction ..GUY ADAMI I agree with..Bargin down here..Merry Christmas
look for 110.00 in january
really what gave it away was the Merry Christmas was used as a spit in the face.I understand he is Jewish but really?